Antibodies against hypocretin receptor 2 are rare in narcolepsy

Sleep

Volumn 40, Issue 2, 2017, Pages

  Giannoccaro, Maria Pia ^a,b   Waters, Patrick ^a   Pizza, Fabio ^b,c   Liguori, Rocco ^b,c   Plazzi, Giuseppe ^b,c   Vincent, Angela ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c BELLARIA HOSPITAL   (Italy)

Author keywords

Antibodies; Autoimmune; HCRTR2; Narcolepsy

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; OREXIN 2 RECEPTOR; OREXIN 2 RECEPTOR ANTIBODY; OXYBATE SODIUM; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VENLAFAXINE; ANTIBODY; HCRTR2 PROTEIN, HUMAN; IMMUNOGLOBULIN G; INFLUENZA VACCINE; OREXIN; OREXIN RECEPTOR;

ADULT; ANTIBODY DETECTION; ARTICLE; CATAPLEXY; CELL ASSAY; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; EMBRYO; EPWORTH SLEEPINESS SCALE; HUMAN; HUMAN CELL; HYPERSOMNIA; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; NARCOLEPSY; NIGHTMARE; PARASOMNIA; POLYSOMNOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOSIS; SCORING SYSTEM; SLEEP; ADOLESCENT; BLOOD; CASE CONTROL STUDY; FEMALE; GENETICS; IMMUNOLOGY; MALE; METABOLISM; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLUENZA VACCINES; MALE; NARCOLEPSY; OREXIN RECEPTORS; OREXINS; VACCINATION;

EID: 85014124015     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/zsw056     Document Type: Article

References (30)

1. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007; 369(9560): 499-511.
2. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000; 355(9197): 39-40.
3. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000; 27(3): 469-474.
4. Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep. 2009; 32(8): 993-998.
5. Matsuki K, Grumet FC, Lin X, et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet. 1992; 339(8800): 1052.
6. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and-DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet. 2001; 68(3): 686-699.
7. Mahlios J, De la Herrán-Arita AK, Mignot E. The autoimmune basis of narcolepsy. Curr Opin Neurobiol. 2013; 23(5): 767-773.
8. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
9. Andlauer O, Moore H 4th, Hong SC, et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep. 2012; 35(9): 1247-155F.
10. Lin L, Hungs M, Mignot E. Narcolepsy and the HLA region. J Neuroimmunol. 2001; 117: 9-20.
11. Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009; 32(8): 979-983.
12. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011; 70(3): 410-417.
13. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One. 2012; 7(3): e33723.
14. Knudsen S, Mikkelsen JD, Jennum P. Antibodies in narcolepsy-cataplexy patient serum bind to rat hypocretin neurons. Neuroreport. 2007; 18(1): 77-79.
15. Martinez-Rodriguez JE, Sabater L, Graus F, et al. Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy. Sleep. 2007; 30(1): 27-28.
16. Black JL III, Silber MH, Krahn LE, et al. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep. 2005; 28(4): 427-431.
17. Tanaka S, Honda Y, Inoue Y, et al. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep. 2006; 29(5): 633-638.
18. Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest. 2010; 120(3): 713-719.
19. Thebault S, Waters P, Snape MD, et al. Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination. PLoS One. 2015; 10(6): e0129555.
20. Black JL III, Krahn LE, Pankratz VS, et al. Search for neuron-specific and non neuron-specific antibodies in narcoleptic patients with and without HLA DQB10602. Sleep. 2002; 25(7): 719-723.
21. Ahmed SS, Volkmuth W, Duca J, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med. 2015; 7(294): 294ra105.
22. Vassalli A, Li S, Tafti M. Comment on Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med. 2015; 7(314): 314le2.
23. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016; 15(4): 391-404.
24. Waters P, Woodhall M, O'Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015; 2(3): e89.
25. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in seronegative myasthenia gravis. Brain. 2008; 131(7): 1940-1952.
26. Dauvilliers Y, Bauer J, Rigau V, et al. Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy. JAMA Neurol. 2013; 70(10): 1305-1310.
27. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev. 2005; 9(4): 269-310.
28. Yamanaka A, Tabuchi S, Tsunematsu T, Fukazawa Y, Tominaga M. Orexin directly excites orexin neurons through orexin 2 receptor. J Neurosci. 2010; 30(38): 12642-12652.
29. Sakurai T. The role of orexin in motivated behaviours. Nat Rev Neurosci. 2014; 15(11): 719-731.
30. Thannickal TC, Siegel JM, Nienhuis R, Moore RY. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol. 2003; 13(3): 340-351.